NEW YORK, Sept. 20, 2016 -- WisdomTree Investments, Inc. (NASDAQ:WETF), an exchange-traded fund ("ETF") and exchange-traded product ("ETP") sponsor and asset manager, today announced the appointment of Anita Rausch as Head of Capital Markets, bringing more than 20 years of industry experience to the role.
Ms. Rausch will be responsible for leading the capital markets efforts in the U.S., Canada and Japan. She will be the senior relationship manager to the trading community and chief educator on the trading ecosystem.
WisdomTree’s Capital Markets team works to provide investors with a positive trading experience through advising on the most efficient ways to trade WisdomTree ETFs. In addition to providing trading guidance, market insight and ETF education, Ms. Rausch and her team will be involved in various aspects of WisdomTree’s ETFs from product development to bringing new products to market, as well as providing ongoing support for our ETF suite.
Jonathan Steinberg, WisdomTree CEO and President said, “Anita is an industry veteran and her deep expertise in capital markets have allowed us to continue to strengthen the ways in which we provide investors with thoughtful ETF trading education and best practices, as well as deeper knowledge on the liquidity and structure of the products.”
Ms. Rausch joined WisdomTree in 2013 as Director of Capital Markets where her responsibilities included broadening and deepening the relationships with the trading community to better connect investors with sources of liquidity.
Prior to joining WisdomTree, Ms. Rausch was an Executive Director on the JP Morgan ETF trading desk where she built trading infrastructure in addition to facilitating trades for all of the firm’s clients across ETFs. She started her career at Morgan Stanley and ultimately became an Executive Director co-heading their ETF trading desk. Ms. Rausch holds a BA in International Business with a minor in German from the George Washington University.
Ms. Rausch will report to Greg Barton, WisdomTree Chief Operating Officer and her new role is effective immediately. The appointment follows a previous announcement that former Head of Capital Markets, David Abner, would be transitioning into a new role as WisdomTree’s Head of Europe.
About WisdomTree
WisdomTree Investments, Inc., through its subsidiaries in the U.S., Europe, Japan and Canada (collectively, "WisdomTree"), is an exchange-traded fund ("ETF") and exchange-traded product ("ETP") sponsor and asset manager headquartered in New York. WisdomTree offers products covering equities, fixed income, currencies, commodities and alternative strategies. WisdomTree currently has approximately $38.7 billion in assets under management globally.
WisdomTree® is the marketing name for WisdomTree Investments, Inc. and its subsidiaries worldwide.
Contact Information Media Relations WisdomTree Investments, Inc. Jessica Zaloom / Melissa Chiles +1.917.267.3735 / +1.917.267.3797 [email protected] / [email protected] Investor Relations WisdomTree Investments, Inc. Stuart Bell +1.917.267.3702 [email protected]


SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition
Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman
Star Entertainment Secures $390M Refinancing Deal to Stabilize Operations
RBC Capital: European Medtech Firms Show Minimal Middle East and Energy Risk Exposure
Brazil Meat Exports Weather Iran War Disruptions With Rerouted Shipments
Ukrainian Drones and the #MadeByHousewives Movement: Kyiv Fires Back at Rheinmetall CEO
Europe's Aviation Sector on Track to Meet 2025 Green Fuel Mandate
Novartis to Acquire Biotech Firm Excellergy in $2 Billion Deal
Cathay Pacific Holds Firm on Flight Capacity Amid Middle East Conflict and Rising Fuel Costs
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026
Jefferies Upgrades Sodexo to Buy With €55 Target After Historic CEO Appointment
McDonald's and Restaurant Brands International Face Headwinds Amid Iran Conflict and Rising Costs
SpaceX Eyes Historic IPO at $1.75 Trillion Valuation
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports
Russell 1000 Companies Hit $2.2T Cash Record While Aggressively Reinvesting in Growth
Eli Lilly and Insilico Medicine Forge $2.75 Billion AI-Driven Drug Discovery Deal 



